A STUDY OF THE PHARMACOLOGY OF 17-HYDROXYPROGESTERONE CAPROATE IN PREGNANCY

17-羟基孕酮己酸酯在妊娠期的药理学研究

• 批准号: 7608328
• 负责人: LANE Arie MENACHEM
• 金额: $ 0.95万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608328
• 关键词: Alternative Therapies; American College of Obstetricians and Gynecologists; Ancillary Study; Computer Retrieval of Information on Scientific Projects Database; Data; Drug Kinetics; Funding; Future; Grant; High Risk Woman; Hydroxyprogesterone Caproate; In Vitro; Institution; Intramuscular; Metabolism; National Institute of Child Health and Human Development; Neonatal; Pharmacodynamics; Pharmacoepidemiology; Pharmacology; Pregnancy; Premature Birth; Prevention; Protocols documentation; Rate; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The recently completed trial by the NICHD sponsored MFMU Network has demonstrated that intramuscular 17-alpha-hydroxyprogesterone caproate (17-OHPC) substantially reduces the rate of preterm birth in women at high risk for preterm delivery because of a prior spontaneous preterm birth (1). No other strategy or treatment for prevention of preterm birth has proven to be effective. Consequently, the American college of Obstetricians and Gynecologists has cautiously supported this treatment but points out that much more information about this therapy and alternative therapies is required (2). Although a large body of evidence exists about the safety of this treatment almost nothing is known about the pharmacology caproate in pregnancy. This protocol will focus on pharmacokinetics and placental transport and provide preliminary data the pharmacoepidemiology of 1-OHPC. Ancillary studies to this protocol will focus on metabolism and In-vitro pharmacodynamics while future studies will focus on in-vvo pharmacodynamics and pharmacoepidemiology. Neonatal pharmacology will also be assessed in the future.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 NICHD赞助的MFMU网络最近完成的试验表明，由于先前的自发早产（1），肌肉内17-α-羟基丙酮类caproate（17-OHPC）大大降低了早产的高风险女性的早产率（1）。 事实证明，没有其他策略或预防早产的疗法是有效的。 因此，美国产科医生和妇科医生谨慎地支持这种治疗方法，但指出需要更多有关这种疗法和替代疗法的信息（2）。 尽管有大量证据证明这种治疗的安全性几乎没有关于怀孕的药理学辅助剂的知识。 该方案将重点关注药代动力学和胎盘运输，并提供初步数据1-OHPC的药物ePidemiology。 该方案的辅助研究将重点放在代谢和维特罗药效学上，而未来的研究将重点放在VVO内药效学和药物ePidemiology上。 新生儿药理学也将在未来进行评估。